Wockhardt Ltd, the Rs 1,100 crore pharmaceutical major which was the first Indian company to launch human insulin this month, is now eyeing the export market for its biotech products, including Wosulin, the recombinant human insulin.
Wockhardt is also planning to launch Hepatitis-A vaccine during the year, which will be its third vaccine product next to Biovac-B and Biovac-T, the typhoid vaccines which were launched in January.
